clinical trial · NCT06455826
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
Retinitis Pigmentosa 11Retinal DegenerationEye DiseasesRetinal DiseaseRetinal DystrophiesVP-001
brief summary
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
started
Jun 13, 2024
primary completion
Sep 23, 2025
completion
Nov 24, 2025
last updated
Apr 13, 2026
official title
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol